Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury

Steven Wink1 · Steven W. Hiemstra1 · Suzanne Huppelschoten1 · Janna E. Klip1 · Bob van de Water1

Received: 21 November 2017 / Accepted: 26 February 2018 / Published online: 3 March 2018
© The Author(s) 2018. This article is an open access publication

Abstract
Drug-induced liver injury remains a concern during drug treatment and development. There is an urgent need for improved mechanistic understanding and prediction of DILI liabilities using in vitro approaches. We have established and characterized a panel of liver cell models containing mechanism-based fluorescent protein toxicity pathway reporters to quantitatively assess the dynamics of cellular stress response pathway activation at the single cell level using automated live cell imaging. We have systematically evaluated the application of four key adaptive stress pathway reporters for the prediction of DILI liability: SRXN1-GFP (oxidative stress), CHOP-GFP (ER stress/UPR response), p21 (p53-mediated DNA damage-related response) and ICAM1 (NF-kB-mediated inflammatory signaling). 118 FDA-labeled drugs in five human exposure relevant concentrations were evaluated for reporter activation using live cell confocal imaging. Quantitative data analysis revealed activation of single or multiple reporters by most drugs in a concentration and time dependent manner. Hierarchical clustering of time course dynamics and refined single cell analysis allowed the allusion of key events in DILI liability. Concentration response modeling was performed to calculate benchmark concentrations (BMCs). Extracted temporal dynamic parameters and BMCs were used to assess the predictive power of sub-lethal adaptive stress pathway activation. Although cellular adaptive responses were activated by non-DILI and severe-DILI compounds alike, dynamic behavior and lower BMCs of pathway activation were sufficiently distinct between these compound classes. The high-level detailed temporal- and concentration-dependent evaluation of the dynamics of adaptive stress pathway activation adds to the overall understanding and prediction of drug-induced liver liabilities.

Keywords High content imaging · Live cell imaging · Adaptive stress pathways · DILI · DILI prediction

Introduction
Despite major efforts to understand and predict drug-induced liver injury (DILI), unpredicted liver failure upon drug use remains an important adverse drug reaction both in the clinic and during drug development (Raschi and de Ponti 2015). To be able to improve prediction of DILI liabilities from new molecular entities integration of mechanistic information is essential. Gene expression analysis has contributed significantly to our understanding of DILI (Laifenfeld et al. 2014; Raschi and De Ponti 2017). This has led to the identification of specific signaling pathways that are activated during DILI and are possibly predictive for chemical-induced liver injury. Key among these are classic stress responses activated to maintain cellular homeostasis, including the oxidative stress response, the endoplasmic reticulum (ER) stress response, the DNA damage response (Laifenfeld et al. 2014) and the TNF signaling pathway (Chen et al. 2015). We have established a panel of fluorescent protein reporter liver cell lines based on transgenomics GFP tagging, that capture each of these four pathways using Srxn1, CHOP, p21 and ICAM1 as quantitative biomarkers (Wink et al. 2017). For the oxidative stress response pathway we have established a Srxn1-GFP reporter (Wink et al. 2017). The
injury (Shaw et al. 2009). Activation of the TNF receptor
by drugs is involved in the pathogenesis of drug-induced liver injury and repair (Chen et al. 2015). The pro-inflammatory cytokine TNFα has a central role in drug-induced liver injury (Tian et al. 2005). Inflammation is involved in the progression of liver injury and CHOP expression is induced by various cytotoxic drugs (Foufelle and Fromenty 2016).

To monitor unfolded protein response (UPR) or ER stress we have established a CHOP-GFP reporter (Wink et al. 2017). The UPR is a protective response upon the accumulation of untranslatable proteins in the ER. UPR activates three classical signaling pathways through PKR-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (Ire1). Activation of PERK leads to arrest of protein translation but permits translation of activating transcription factor 4 (ATF4) which on its turn targets expression of ER function-related proteins including transcription factor C/EBP homologous protein (CHOP). Also activation of the Ire1 and ATF6 ER stress pathways can induce CHOP expression (Li et al. 2014). CHOP modulates the expression of many genes, including apoptotic machinery components. CHOP expression seems linked to the progression of liver injury and CHOP expression is induced by various cytotoxic drugs (Foufelle and Fromenty 2016).

To monitor DNA damage we established a fluorescent protein reporter for the p53 downstream target gene p21 (Wink et al. 2017). The cellular protective response upon DNA damage induces cell cycle arrest and subsequent senescence (Wink et al. 2014). p53 can be activated upon DNA damage as well as other cellular stresses, and induces expression of many target genes, including p21 (El-Deiry 2016). The best-characterized function of p21 is its effective inhibition of cyclin-dependent kinases (CDK), which halts the progression of the cell cycle. Localization of p21 has been found both in the nucleus and the cytoplasm (Cmielová and Řezáčová 2011). In the liver, in vivo studies show upregulated p21 nuclear expression upon drug exposure, mostly via p53 activation (Bandi et al. 2011; Yafune et al. 2013).

Finally, a fluorescent reporter for ICAM1 allows monitoring the cytokine-mediated activation of NF-κB signaling (Tian et al. 2005). Inflammation is involved in drug-induced liver injury and repair (Chen et al. 2015). The pro-inflammatory cytokine TNFα has a central role in drug-induced liver injury (Shaw et al. 2009). Activation of the TNF receptor causes nuclear translocation of the transcription factor nuclear factor κB (NF-κB) driving the expression of various pro-inflammatory molecules, including intercellular adhesion molecule 1 (ICAM1) (Brenner et al. 2015). ICAM1 is expressed at the membrane of TNFα-activated hepatocytes, facilitating the adherence of leukocytes (Rahman and Fazal 2009). ICAM1 is widely used as a marker for inflammation and ICAM1 expression is also increased upon inflammation in the liver (Hoque et al. 2013).

Given the central role of the above stress response pathways in liver injury, our objective was to evaluate the application of our panel of target gene GFP reporter cell lines that represent these four major adaptive stress response pathways to predict DILI liability. Previously, we demonstrated that the GFP reporters allow the quantification of the chemical-induced stress responses similar to primary human hepatocytes (Wink et al. 2017). Here, we systematically determined the application of our Srxn1-GFP, CHOP-GFP, p21-GFP and ICAM1-GFP reporters for the assessment of DILI using a set of 118 FDA-labeled drugs with defined DILI drug label classification. The concentration- and time-dependent GFP responses were determined in association with general markers of cytotoxicity. In this study, we established quantitative information of the dynamic adaptive stress response activation by all 118 drugs allowing detailed mode-of-action assessment. We used the temporal dynamic stress response activation data together with concentration response modeling for the prediction of DILI outcome.

Materials and methods

Raw data

All image-derived data has been made publicly available at the EMBL-EBI BioStudies repository, under accession number S-BSST117.

Cell culture

Human hepatoma HepG2 cells were acquired from ATCC (clone HB8065). HepG2 Srxn1, DDIT3 (CHOP), CDKN1A (p21) and ICAM1 BAC GFP reporter cell lines were previously established and characterized (Wink et al. 2017). HepG2 BAC GFP reporters were maintained and exposed to drugs in DMEM high glucose supplemented with 10% (v/v) FBS, 25 U/mL penicillin and 25 µg/mL streptomycin. The cell lines were used between passage 5 and 25. For live cell imaging, the cells were seeded in Greiner black µ-clear 384 wells plates, at 8000 cells per well.
Reagents

All reference compound chemicals were acquired from Sigma–Aldrich and freshly dissolved in DMSO; except for metformin (PBS), acetaminophen and phenobarbital (all DMEM). TNFα was acquired from R&D Systems (Abingdon, UK). All 118 DILI compounds were a kind gift from the Dr. Weida Tong, NCTR-FDA (Chen et al. 2011). All compounds were maintained as 500-fold stock such that final treatments did not exceed 0.2% v/v DMSO.

Microscopy

Accumulation of GFP levels, propodium iodide (PI) and Hoechst staining was monitored using a Nikon TiE2000 confocal laser microscope (lasers 540, 488 and 408 nm), equipped with an automated stage and perfect focus system at 37 °C with humidified atmosphere and 5% CO2/air mixture. All imaging was similar as previously described5. Each 384-well plate contained one reporter cell line, which was exposed to all the compounds used in the screen at one concentration (1, 5, 10, 50 or 100 Cmax); for each concentration at least two replicates were imaged per reporter cell line. For the ICAM1-GFP reporter experiments, cells were first exposed for 8 h to compound only; next, TNFα was added to all wells, up to a final concentration of 10 ng/mL. Directly after TNFα treatment the live cell imaging was started.

Image analysis of fluorescent protein reporter activity

Quantitative image analysis was performed with CellProfiler version 2.1.1 (Kamentsky et al. 2011) with an in house developed CellProfiler module implementing the watershed masked algorithm for segmentation (Yan and Verbeek 2012; Wink et al. 2017). Image analysis results were stored as HDF5 files. Data analysis, quality control and graphics were performed using the in house developed R package h5CellProfiler (manuscript in preparation). For each reporter hourly intensity levels of the GFP signal, the nuclear Hoechst intensity levels and at 24 h the PI staining were measured at the single cell level. In addition, cell numbers, nuclei size and cell motility were measured.

Data analysis

GFP intensity cell population means were calculated. In addition, for each plate the cell population mean GFP intensity of the DMSO treated cells was calculated to determine background control values. Per plate, the single cells that had values above the 2X mean, 3X mean were counted resulting in GFP positive fraction measures. For ICAM1, the background control values consisted of DMSO conditions treated with TNFα, and the single cells with values above, as well as below background values were counted. Due to the non-symmetric distribution of ICAM1 cell population GFP intensities, the interquartile range (IQR) was used to count the number of cells 1.5, 2 and 3 times above and below the TNFα IQR control values (Supplemental Fig. 1).

To account for PI background staining noise the PI segmentations were masked by a 2 pixel dilated nuclei. The area of these nuclei and the PI objects were divided to obtain a PI/nuclei ratio. These ratios were filtered to be at least 10% of the cell size and following this procedure each cell was either flagged as alive or dead in the final time point of the 24 live imaging session. PI positive fraction was normalized to DMSO (or TNFα for ICAM1) by subtracting the control PI positive fractions.

Linear regression was applied with respect to time to quantify treatment effects on a plate-to-plate basis to quantify cell speed, nuclear size, Hoechst nuclear intensity and cell numbers. The slope coefficient mean over all plates was used to obtain a compound-concentration specific summary statistic. All summary features were scaled between 0 and 1 with the formula (x − xmin_replicate)/(xmax_replicate − xmin_replicate), with the exception of (1) the cell count features which were scaled between 0 and 1 by calculating cell fractions and (2) the ICAM1 intensity features which were scaled between −1 and 1 to account for up or down regulation of the TNFα-induced ICAM1-pathway (Supplemental Fig. 1).

Concentration response data transformation and benchmark concentration (BMC) modeling

The maximum values over time of the scaled intensity levels and positive GFP fractions were selected for the concentration response curves. These values were fit to a four parameter log-logistic model using the drc package (Ritz et al. 2015). BMC values were calculated as the concentration at which +0.25 (and −0.25 for ICAM1) absolute increase from the initial response values occurred (Fig. 5a).

The replicate means of the maximum over time features were calculated for each compound-concentration preceding unsupervised hierarchical clustering.

For the time course analysis natural cubic splines with 8° of freedom were fit after which 24 discrete equidistant time points were selected to calculate per-time point replicate means. The time course hierarchical clustering was performed by first calculating Manhattan based distances between all time-course vectors. The mean Manhattan based distances over all reporters was used as inputs for the Ward based clustering. This ensured appropriate clustering of also the temporal dynamics.
Data representation

All HCI data representations were generated or modified with Illustrator CS6, Fiji, ggplot2 (Wickham 2009), the ‘ahem’ function of the NMF package (Gaujoux and Seoighe 2010).

Severe vs non-severe DILI prediction with support vector machine

FDA DILI-annotation was used as ‘ground truth’ with non-DILI (n = 16), less-severe DILI (n = 36) and ambiguous DILI (n = 12) grouped as ‘non-severe DILI’ and severe-DILI (n = 54) as ‘severe DILI’ resulting in a two-classification problem. Features were obtained by time dynamic feature extraction of time courses with functional data analysis using the in house developed R-package ‘celloscillate’ and the BMC and C-max normalized BMC values. Feature selection and SVM model tuning was performed in a 200 times iterative process with randomly selected 80/20—equal class distributed training/test set procedure. The training phase included a first feature selection step using a Kolmogorov–Smirnov test for equal distributions between the two classes followed by pair-wise correlation filter step (> 0.8 or < −0.8). The second step in the training phase consisted of the SVM model tuning with ten repeats of 10-fold cross-validation. The test phase on 20% of the compounds was performed using the selected features and tuned SVM model. Reported prediction results are the average of the 200 test-set runs; the ROC distribution of the test-runs were defined. Hierarchical clustering of the 20 selected features corresponded to the features selected > 150 times through the 200 iterations.

Gene expression analysis

CEL files were downloaded from the Open TG-GATEs database: “Toxicogenomics Project and Toxicogenomics Informatics Project under CC Attribution-Share Alike 2.1 Japan” https://dbarchive.biosciencedbc.jp/en/open-tggates/desc.html and analyzed as described previously (Wink et al. 2017).

Statistics

For all reporters and concentrations three independent biological replicate imaging experiments were performed, of which upon selection of cell viability of untreated control conditions, at least two replicates were used for the quantification of reporter activity and further statistical analysis. For statistical significance of all time courses first linear interpolation was applied for each separate time course using the ‘approx’ function from the R-stats package to obtain 100 equal discretized time points for each replicate. The high number of linear interpolations was required to retain the original noise in the time course data. Following this step,
| Compound          | $C_{\text{max}}$ ($\mu$) | Abb. | DILI con. | Severity | Hepa. | $C_{\text{max}}$ ref. | Metab  |
|-------------------|--------------------------|------|-----------|----------|-------|------------------------|--------|
| Acarbose          | 0.15                     | ACA  | Most-DC   | Sev. 8   | FDA   | NA                     | NM     |
| Acetaminophen     | 1.39                     | APAP | Most-DC   | Sev. 5   | Xu/O'Brien | NA                  | YES    |
| Adefovir          | 0.085                    | ADV  | Less-DC   | Non-sev. 2 | Dailymed | NA                  | NM     |
| Allopunol         | 13.81                    | ALLO | Most-DC   | Sev. 8   | FDA   | NA                     | NM     |
| Alretamine        | 3.76                     | ALM  | Amb.-DC   | Non-sev. 2 | FDA   | NA                     | YES    |
| Amiodarone        | 0.807                    | AMIO | Most-DC   | Sev. 8   | Xu/O'Brien/Khet. | NA      | NM     |
| Amoxicillin       | 22.3                     | AX   | Less-DC   | Non-sev. 5 | FDA   | NA                     | NM     |
| Azathioprine      | 0.34                     | AZA  | Most-DC   | Sev. 5   | FDA   | NA                     | YES    |
| Benz bromarone    | 4.339                    | BB   | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Betaine           | 940                      | BET  | No-DC     | Non-sev. 1 | O'Brien | NA                  | NM     |
| Bicalutamide      | 1.97                     | BAT  | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Bosentan          | 7.4                      | BOS  | Most-DC   | Sev. 7   | Dawson/Gustaf. | NA      | YES    |
| Bromfenac         | 17.96                    | BFC  | Most-DC   | Sev. 8   | FDA   | NA                     | NA     |
| Buspirone         | 0.016                    | BUS  | Amb.-DC   | Non-sev. 3 | FDA   | NA                     | YES    |
| Busulfan          | 0.277                    | BU   | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Captopril         | 8.882                    | CPL  | Less-DC   | Non-sev. 7 | FDA   | NA                     | YES    |
| Carbamazepine     | 50.79                    | CBZ  | Most-DC   | Sev. 7   | Dailymed | NA                  | NM     |
| Chloramphenicol   | 46.13                    | CAMP | No-DC     | Non-sev. 1 | Ogutu   | NA                  | NA     |
| Chlorizanone      | 10.59                    | CMZ  | Most-DC   | Sev. 8   | FDA   | NA                     | NA     |
| Chlorpromazine    | 0.94                     | CPZ  | Less-DC   | Non-sev. 2 | Xu   | NA                     | YES    |
| Chlorpropamide    | 130.1                    | CHL  | Less-DC   | Non-sev. 2 | FDA   | NA                     | NM     |
| Cimetidine        | 11.89                    | CMT  | Less-DC   | Non-sev. 2 | Regenthal | NA              | YES    |
| Ciprofloxacin     | 6.58                     | CIPX | Most-DC   | Sev. 7   | FDA   | NA                     | YES    |
| Clorbrate         | 470                      | CLO  | Less-DC   | Non-sev. 3 | O'Brien | NA                  | YES    |
| Clotrimazol        | 0.087                    | CTZ  | Less-DC   | Non-sev. 3 | FDA   | NA                     | NM     |
| Clozapine         | 2.44                     | CLZ  | Most-DC   | Sev. 5   | Regenthal | NA                | YES    |
| Colchicine        | 0.016                    | CLC  | Amb.-DC   | Non-sev. 6 | FDA   | NA                     | YES    |
| Cyclosporin A     | 0.2                      | CSA  | Most-DC   | Sev. NA   | Dailymed | NA              | YES    |
| Dacarbazine       | 20.64                    | DTIC | Most-DC   | Sev. 6   | FDA   | NA                     | NM     |
| Danazol           | 0.109                    | DNZ  | Most-DC   | Sev. 8   | FDA   | NA                     | NA     |
| Dantrolene        | 7.9                      | DAN  | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Dexamethasone     | 0.224                    | DXS  | Amb.-DC   | Non-sev. 3 | FDA   | NA                     | NM     |
| Dextromethorphan hbr | 0.022              | DXM  | No-DC     | Non-sev. NA | Xu   | NA                     | NA     |
| Diclofenac        | 10.1                     | DCF  | Most-DC   | Sev. 8   | Gustaf./Regen. | NA      | YES    |
| Didanosine        | 9.83                     | DDL  | Most-DC   | Sev. 8   | FDA   | NA                     | NM     |
| Diethylmalate     | 5.4                      | DEM  | Control   | Na NA    | NA     | NA                     | NA     |
| Digoxin           | 0.003                    | DIG  | No-DC     | Non-sev. 1 | FDA   | NA                     | YES    |
| Diltiazem         | 0.356                    | DTZ  | Most-DC   | Sev. 4   | Pat el | NA                     | YES    |
| Disulfiram        | 5.4                      | DIS  | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Dmso              | 0.2                      | DM SO | Control   | Na NA    | NA     | NA                     | NA     |
| Edrophonium       | 60.2                     | EDR  | No-DC     | Non-sev. 1 | FDA   | NA                     | NA     |
| Enalapril         | 0.4                      | ENP  | Less-DC   | Non-sev. 7 | FDA   | NA                     | YES    |
| Entacapone        | 3.93                     | ECP  | Less-DC   | Non-sev. 1 | Dailymed | NA              | YES    |
| Epinephrine       | 0.002                    | EPI  | No-DC     | Non-sev. 1 | FDA   | NA                     | NA     |
| Erythromycin      | 11                       | ERVC | Most-DC   | Sev. 5   | FDA   | NA                     | NM     |
| Ethambutol        | 24.47                    | EMB  | Most-DC   | Sev. 8   | FDA   | NA                     | NM     |
| Etodolac          | 68.49                    | ELAC | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
| Etoposide         | ETO                      | Control | Na NA    | NA NA    | NA     | NA                     | YES    |
| Famotidine        | 0.308                    | FAM  | Less-DC   | Non-sev. 3 | FDA   | NA                     | YES    |
| Fenofibrate       | 4.1                      | FF   | Less-DC   | Non-sev. 3 | FDA   | NA                     | NM     |
| Fenoprofen        | 58.2                     | FPF  | Most-DC   | Sev. 8   | FDA   | NA                     | YES    |
Table 1 (continued)

| Compound     | C<sub>max</sub> (μ) | Abb. | DILI con. | Severity | Hepa. | C<sub>max</sub> ref. | Metab |
|--------------|---------------------|------|-----------|----------|------|---------------------|-------|
| Fialuridine  | 1                   | FLA  | Most-DC   | Sev.     | 8    | O’Brien             | NA    |
| Fluoxetine   | 0.05                | FLX  | Less-DC   | Non-sev. | 3    | Regenthal           | YES   |
| Flurbiprofen | 57.32               | FBP  | Amb.-DC   | Non-sev. | 3    | FDA                 | YES   |
| Folic acid   | 0.043               | FAM  | No-DC     | Non-sev. | 1    | FDA                 | YES   |
| Furosemide   | 3.29                | FUR  | Amb.-DC   | Non-sev. | 2    | FDA                 | YES   |
| Ganciclovir  | 4.62                | GOV  | Amb.-DC   | Non-sev. | 7    | FDA                 | YES   |
| Glimepiride  | 1.12                | GLP  | Less-DC   | Non-sev. | 7    | FDA                 | NM    |
| Griseofulvin | 4.54                | GF   | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Haloperidol  | 0.005               | HDL  | Less-DC   | Non-sev. | 5    | FDA                 | YES   |
| Hydroxyzine  | 0.27                | HVZ  | No-DC     | Non-sev. | 1    | FDA                 | NM    |
| Imipramine   | 0.29                | IM   | Less-DC   | Non-sev. | 3    | FDA                 | YES   |
| Indomethacin | 5.59                | IMN  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Ibuprofen    | 57.32               | FBP  | Amb.-DC   | Non-sev. | 3    | FDA                 | YES   |
| Isoproterenol| 2.02                | IPR  | No-DC     | Non-sev. | 1    | Gustafsson          | NA    |
| Kanamycin    | 60.1                | KM   | No-DC     | Non-sev. | 1    | FDA                 | NM    |
| Ketoconazole | 6.59                | KTZ  | Amb.-DC   | Non-sev. | 3    | FDA                 | NM    |
| Kloralazine  | 2.62                | LABE | Most-DC   | Sev.     | 8    | FDA                 | VES   |
| Maprotiline  | 0.18                | MPT  | Amb.-DC   | Non-sev. | 5    | FDA                 | NA    |
| Mebendazole  | 0.13                | MBZ  | Less-DC   | Non-sev. | 3    | FDA                 | NM    |
| Meclozine    | 0.026               | MCZ  | No-DC     | Non-sev. | 1    | FDA                 | NM    |
| Mercaptopurine| 0.48               | 6MP  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Metformin    | 7.78                | MF   | Less-DC   | Non-sev. | 3    | FDA                 | NM    |
| Methimazole  | 2.62                | MTZ  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Methotrexate | 0.77                | MXT  | Most-DC   | Sev.     | 3    | FDA                 | NM    |
| Methyldopa   | 18.94               | MD   | Most-DC   | Sev.     | 8    | Regenthal           | NM    |
| Metoprolol   | 0.56                | MTPL | Less-DC   | Non-sev. | 5    | FDA                 | YES   |
| Mexiletine   | 3.83                | MXT  | Most-DC   | Sev.     | 3    | FDA                 | YES   |
| Moxisylyte   | 0.16                | MOX  | Most-DC   | Sev.     | 8    | FDA                 | NA    |
| Naproxen     | 0.2                 | NPX  | Less-DC   | Non-sev. | 3    | Regenthal           | YES   |
| Nefazodone   | 3.95                | NFZ  | Most-DC   | Sev.     | 8    | Gustaf./Regen./Daw. | YES   |
| Neomycin     | 0.44                | NEO  | No-DC     | Non-sev. | 1    | Hu: in vitro dose   | NM    |
| Nifedipine   | 0.43                | NFP  | Less-DC   | Non-sev. | 3    | Wagner              | YES   |
| Nimesulide   | 21.082              | NMS  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Nitrofurantoin| 6                 | NTF  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Nizatidine   | 4                   | NIZ  | Less-DC   | Non-sev. | 5    | FDA                 | YES   |
| Ofloxacin    | 9.96                | OFX  | Less-DC   | Non-sev. | 3    | Dailymed            | NM    |
| Omeprazole   | 4.7                 | OMZ  | Less-DC   | Non-sev. | 4    | Dailymed            | YES   |
| Oxytetracycline| 3.26              | OTC  | Amb.-DC   | Non-sev. | 2    | FDA                 | NA    |
| Paroxetine   | 0.061               | PXT  | Less-DC   | Non-sev. | 8    | FDA                 | YES   |
| Perhexiline  | 2.16                | PHX  | Most-DC   | Sev.     | 8    | FDA                 | NA    |
| Phenobarbital| 145.5               | PBT  | Less-DC   | Non-sev. | 3    | Schmidt             | NM    |
| Phenytoin    | 21.72               | PBT  | Most-DC   | Sev.     | 8    | Xu et al            | YES   |
| Piroxicam     | 2.946              | PGI  | Less-DC   | Non-sev. | 3    | Xu/O’Brien          | NM    |
| Prednisolone | 0.68                | PRD  | Less-DC   | Non-sev. | 3    | FDA                 | NM    |
| Primidone    | 4.67                | PRI  | No-DC     | Non-sev. | 1    | FDA                 | NM    |
| Propochin    | 0.404               | PCD  | No-DC     | Non-sev. | 1    | FDA                 | NA    |
| Propranolol  | 0.201               | PPL  | Amb.-DC   | Non-sev. | 3    | FDA                 | YES   |
| Propylthiouracil| 9.1               | PTU  | Most-DC   | Sev.     | 8    | FDA                 | YES   |
| Ranitidine   | 1.79                | RNT  | Less-DC   | Non-sev. | 5    | FDA                 | YES   |
a one-way ANOVA for functional data method was applied using the ‘anova.onefactor’ function of the R-package fda. usc to determine significant difference in time-curves compared to DMSO for Srxn1/CHOP/p21 or TNFα for ICAM1. Multiple testing correction was applied using the fdr-method (Benjamini and Hochberg). Srxn1/CHOP/p21 were assessed for significant upregulation and ICAM1 for significant down- or up-regulation.

For the log-BMC values a linear model with the BMC and C-max as explanatory variables was fit as null-model. The null-model was compared in an anova to a model containing DILI-class as additional additive explanatory variable. The models were compared in an anova for significant effect of DILI-class.

For the C-max normalized BMC a Welch two-sample t test was performed between the severe and non-severe DILI groups.

### Results

**High content adaptive stress response screen with DILI compounds**

To assess the application of adaptive stress response pathway activation for assessment of adverse drug reactions, we focused on DILI. For the assessment of DILI liabilities we screened 123 compounds, of which 118 with known DILI liabilities (Fig. 1; Table 1). As an adaptive stress response read-out, HepG2 BAC-GFP reporter cell lines for oxidative stress (Srxn1-GFP), ER-stress (CHOP-GFP), DNA damage (p21-GFP) and inflammatory cytokine signaling stress (ICAM1-GFP) were used [Wink et al. 2017] and see Suppl. Figure 2. Stress response activation following DILI drug exposure was monitored with live cell confocal microscopy for a period of 24 h. The time-resolved single cell data was quantified using an established image analysis pipeline (Wink et al. 2017). For labeling DILI compounds we used the FDA DILI labeling, which labels drugs either as no-DILI-concern, ambiguous DILI-concern, less-severe...
DILI concern or most-severe-DILI-concern (Chen et al. 2016). Most-severe-DILI-concern drugs are highly associated with DILI and represent multiple specialist verified cases of DILI. Less-severe-DILI-concern drugs represent few verified cases of DILI. If drugs are suspected to cause most- or less-severe-DILI-concern, but the presented cases cannot be validated by experts, drugs received the ambiguous DILI-concern label. No-DILI-concern drugs are on the market for decades and have never been associated with DILI. To separate out clear examples of DILI, we made two classes: ‘non-severe-DILI’ and ‘severe-DILI’, where the most-severe-DILI-concern drugs comprised the ‘severe-DILI’ group and all others are in the ‘non-severe-DILI’ group. In addition, we included FDA labeling in eight separate classes of hepatotoxicity ranging from no hepatotoxicity to fatal hepatotoxicity (Table 1). The screen also included reference compounds including negative controls (DMSO and medium) and positive controls (i.e. DNA damage inducers, soft electrophilic alkylating agents and ER stress inducers) (see Table 1; Fig. 2).

**Single cell analysis of adaptive stress response activation**

All reporters were exposed to five concentrations: 1, 5, 10, 50 and 100 C-max followed by automated live cell imaging and multi-parametric image analysis (Fig. 1); C-max values were obtained either from FDA or from literature (see Table 1) (Schmidt et al. 1986; Regenthal et al. 1999; Ogutu et al. 2002; Ravic et al. 2004; O’Brien et al. 2006; Xu et al. 2008; Andersson and Keisu 2010; Nidhi et al. 2011; Patel et al. 2011; Dawson et al. 2012; Hu and Coates 2013; Khetani et al. 2013; Gustafsson et al. 2014). For all images single cell analysis was performed to extract a diverse set of quantitative data, including GFP reporter activity, cell number and markers of cytotoxicity (Suppl. Figure 1). Srnx1-GFP, p21-GFP and CHOP-GFP reporter single cell data was used to derive quantitative data for different determinants of reporter activity: intensity and fraction of cells with GFP intensity levels above control values. Fraction of cells with GFP intensity were divided in three types: two times or three times the mean of the control values (i.e. %GFP positive 2 m and %GFP positive 3 m, respectively); and the control mean plus three times the standard deviation of the mean (%GFP positive m3sd). All ICAM1-GFP reporter drug exposures were primed with TNF-α exposure; likewise, ICAM1-GFP shows a gradual increase over 24 h time period in the vehicle control. As a consequence, drug treatment can lead to an enhancement or inhibition of the TNF-α induced ICAM1-GFP response. ICAM1-GFP fractions were calculated as the difference between up- and downregulated fractions (%GFP diff. 2 m). Systemic evaluation of these descriptors for the least and strongest responding compound for each individual reporter allowed fine tuning of the sensitivity versus the dynamic range (Fig. 2). For example, based on the Srnx1-GFP intensity over the single cell population chlorpromazine would not have been defined as positive in the Srnx1-GFP reporter cell line, because only in a small proportion of cells that contain a higher level of Srnx1-GFP the signal was detected. Yet, the %GFP positive 2 m and %GFP positive 3 m were more sensitive descriptors that also allowed evaluation of the time course dynamics for chlorpromazine. Similar observations were made for nitrofurantoin and clozapine for the CHOP-GFP and p21-GFP reporters, respectively. However, for strong inducers of oxidative stress (diethylmaleate; DEM), ER-stress (thapsigargin) and DNA damage (etoposide), GFP mean intensity already allowed detection of the reporter responses, while %GFP positive 2 m caused an early saturation, thereby lowering the information value of the temporal dynamics. Further, diclofenac (DCLF) and azathioprine (AZA) showed inhibiting and enhancing modulatory effects on TNF-α-induced ICAM1-GFP, respectively.

**DILI compounds demonstrate specific stress response reporter activation dynamics**

For the evaluation of the reporter activation for the entire screen %GFP positive 2 m was selected as the most sensitive initial readout. The %GFP positive 2 m time courses were used to calculate the mean of the replicates for Srnx1-GFP, CHOP-GFP, p21-GFP and ICAM1-GFP reporter responses for all compounds (Fig. 3a and Suppl. Figure 3). Some compounds showed a response in all four reporters. Thus, methyldopa (MD) increased Srnx1-GFP, CHOP-GFP, p21-GFP and ICAM1-GFP activity and inhibited the ICAM1-GFP response. Mercaptopurine (6MP) increased all four reporters. The data also allowed discrimination of specific time dynamics of stress activation. Thus, for nimesulide (NMS), rifampicin (RFP) and oxytetracycline (OXY) an initial CHOP-GFP response at 100× C-max and a delayed Srnx1-GFP response was observed. In contrast, for azathioprine (AZA), colchicine (CLC) and dacarbazine (DTIC) a Srnx1-GFP response was later followed by CHOP-GFP, suggesting ER-stress as the primary...
Hierarchical clustering of the time courses from all 118 compounds representing the reporter activities from all BAC-GFP reporter cell lines demonstrated a large cluster with considerable modulation of stress response reporter activity (Fig. 3b and Suppl. Figure 4). This cluster showed an overrepresentation of severe-DILI compounds as well as more severe classes of hepatotoxicity (liver necrosis, acute liver failure and fatal hepatotoxicity). Sub-clusters with activation of all four reporters were established, with ICAM1-GFP either up- or downregulated. p21-GFP did show few responses and did not contribute much to the DILI compound clustering, in
overall agreement with anticipated overall lack of DNA damage of marketed drugs, excluding anticancer drugs. The time response clearly demonstrated the dynamics of the various stress response programs and allowed discrimination between primary stress types and subsequent secondary responses. Strikingly, suppression by DILI compounds of the cytokine-induced ICAM1-GFP expression was highly correlated with activation of the CHOP-GFP reporter, which in a few cases was co-occurring with Srxn1-GFP activation.

**Concentration response analysis reveals strong clustering of severe DILI compounds**

Next, we summarized time course data by extracting the time point at which the reporter expression reached a peak response using the various quantitative GFP reporter activity descriptors as well as cytotoxicity measurements. Hierarchical clustering revealed a stress response reporter active group divided over three sub-groups and one large non-activated group (Fig. 4). For the active group one sub-group was marked by an increase in Srxn1-GFP, CHOP-GFP and (for some compounds) p21-GFP in combination with a decrease in ICAM1-GFP. A second sub-group was characterized by a strong increase in CHOP-GFP and cytotoxicity as well as a strong decrease in ICAM1-GFP. For the third sub-group both Srxn1-GFP and ICAM1-GFP reporters showed a clear increase. Most of the severe-DILI compounds were present in one of the active sub-groups. The point-of-departure (PoD) varied between reporters. For example mercaptopurine showed a relatively strong activation of both Srxn1-GFP and ICAM-GFP, yet, the PoD for ICAM-GFP response was at a lower C-max than for the onset the Srxn1-GFP response. In contrast, ketoconazole showed no Srxn1-response at the intensity feature level but only at the more sensitive %GFP positive marker starting earliest at 50 C-max as the primary and only stress-type. Thus, the current high content data analysis revealed the value of measuring quantitative adaptive stress responses for the different DILI classes with a clear distinction in primary stress responses for individual DILI compounds.

**Benchmark concentrations definition reveals low PoD for Srxn1-GFP and CHOP-GFP activation in the severe DILI group**

Based on the concentration response curves extracted from the peak response in %GFP positive 2 m (Srxn1-GFP, CHOP-GFP and p21-GFP) and %GFP diff. 2 m (ICAM1-GFP) we defined the benchmark concentration (BMC; defined as at least 25% of the cells that reach the two times average threshold of the control values: see Fig. 5a). This BMC can function as an indicator for the PoD for further risk assessment modeling. The C-max values for the 118 DILI compounds covered a large concentration range from 1.7 nM to 0.94 mM. Therefore, we plotted the BMC against the absolute C-max value (Fig. 5b) and we divided the BMC by the absolute C-max (Fig. 5c). We observed a lower BMC in Srxn1-GFP, CHOP-GFP and ICAM1-GFP for severe DILI compounds compared to non-severe DILI compounds. This indicates that severe DILI compounds have a lower PoD and are, therefore, more potent to activate adaptive stress response pathways.

**Stress response reporter activity SVM classification and prediction of DILI liability**

Next, we extracted the time dynamic features and BMC values for all 118 DILI compounds for the different reporters culminating in 273 different features. Machine learning was applied to assess temporal stress pathway activation and concentration—response relations for predictive power and feature relevance. Feature selection and support vector machine (SVM) model tuning were performed over 200 iterations of random training/test dataset sampling (Suppl. Figure 1). The features selected more than 150 times in the 200 iterations were subjected to unsupervised hierarchical clustering (Fig. 6b). Interestingly, this set included a diverse set of features, encompassing all reporters, BMC, C-max and also cytotoxicity features including cell death with TNFα at 10 C-max, cell death at 100 C-max and cell speed at 50 C-max. Early and late slope features from the reporters seem to be preferred over the max magnitude values. The resulting clustering with these features showed three dominant sub-groups with enriched severe DILI compounds (Fig. 6b).

The 200 independent test-set prediction validations with the tuned SVM model resulted in an average ROC of 0.73 (Fig. 6c, left panel) and a sensitivity of 0.60 and specificity of 0.75 with ‘positive’ being the severe-DILI group. Over the 200 runs the correct prediction rates for each compound was calculated (Fig. 6c, right panel). 88 DILI compounds were consistently either predicted correctly or predicted falsely. A smaller set of 30 compounds have some uncertainty as to being predicted correctly. No enrichment for DILI-class can be seen for these prediction rates.

**Discussion**

Here, we systematically evaluated the application of a panel of four key adaptive stress response fluorescent protein reporters in high content high throughput screening as a method for DILI liability assessment. We anticipate that adaptive stress pathway activation respond well before the
onset of overt toxicity, thus ensuring increased sensitivity as well as integration of detailed quantitative mechanistic information in chemical safety assessment. We monitored four downstream adaptive stress response pathways represented by Srxn1 (Nrf2 oxidative stress response), CHOP (ER-stress/UPR response), p21 (p53 dependent DNA damage-related signaling) and ICAM1 (NFκB-mediated pro-inflammatory cytokine signaling). Systematic image analysis revealed specific activation of Srxn1-GFP and CHOP-GFP by severe DILI versus non-severe DILI inducing drugs. A subset of dynamic features across all cell reporters allowed the classification of severe versus non-severe DILI classes with a sensitivity of 60% and a specificity of 75%. We demonstrate the application of advanced dynamic high content imaging data of stress response signaling can be integrated with informatics approaches for DILI inducing liability assessment of candidate drugs. This mechanism-based assessment is a

Fig. 4 Hierarchical clustering of peak GFP response in time Hierarchical clustering of responses of intensity and count related GFP responses in dose response fashion. Cell death measurements cell number and PI staining are in the right bar. On the left side DILI labeling is depicted in three bars: severe/non-severe, DILI-concern labeling and hepatotoxicity class labeling. Compound names are colored based on the unsupervised clustering. (Color figure online)

Fig. 5 Benchmark concentration (BMC) versus the absolute C-max values per reporter. a Explanation of how we extract BMC from the fitted dose ranges from different GFP reporters. b For each reporter the absolute BMC (y-axis) is plotted against the absolute C-max (x-axis), each dot represents a compound which reached the 0.25 threshold. Purple indicates a severe DILI drug, Light blue indicates a non-severe drug: * = p < 0.05 and ** = p < 0.01. c The BMC is divided by the absolute C-max value per compound and represented in the severe/non-severe DILI classes and per reporter; * = p < 0.05 and ** = p < 0.01. (Color figure online)
Fig. 6 Prediction of severe versus non-severe DILI groups. a Explanation of temporal feature extraction. b Feature selection by Kolmogorov Smirnov test and pairwise correlation filter. Followed by unsupervised hierarchical clustering of the most often selected features from the 200 feature selection iterations. c ROC curves from 200 test data runs and average prediction results (left); Fraction of correct prediction for each drug

**Feature Selection and Unsupervised Clustering**

- Time dynamic feature extraction
- ROC curves 200 test-set runs: median ROC = 0.73
- Specificity 0.75
- Balanced Accuracy 0.67
- True Positive Rate (Sensitivity) 0.75
- False Positive Rate (1-Specificity) 0.25
- Median values after 200 runs:
  - 80/20 train/test set prediction validation

**Unsupervised Hierarchical Clustering of Selected Features**

- Total of 20 features
- Reporter Type
- DILI Concern
  - No-DILI-Concern
  - Ambiguous DILI-concern
  - Least-DILI-Concern
  - Most-DILI-Concern

**Assessing Predictive Power Severe vs Non-severe DILI with Support Vector Machine Classification**

- **ROC curves 200 test-set runs:** median ROC = 0.73
- **Compound correct prediction rates**
  - Severe
  - Non-Severe
  - Feature: 273

**Resulting dataset**

- 5 time features
- 3 GFP cell positive fraction features
- GFP intensity feature
- slope cell count
- slope cell migration
- slope nuclear hoestch stain
- slope nuclear area
- end value PI positive fraction
- end value PI positive fraction with TNF
- BMC, cmax & BAC/Cmax
- 5 concentrations
- 4 reporters
- Total of 273 features

**Feature Selection**

- Test equal distributions (Kolmogorov-Smirnov)
- Filter p-value < 0.05 (62 features)
- Remove pair wise correlated features
- -0.8 < cor < 0.8

**Reporters**

- 4 reporters
- 5 concentrations
- end value PI positive fraction
- slope nuclear hoechst stain
- GFP intensity feature
fast and transparent approach to integrate mode-of-action information in prioritizing lead compounds early in the drug development cycle.

Our adaptive stress response reporters provide detailed information on the adverse mode-of-action of different drugs. We observed three different clusters of DILI inducing drugs with clear reporter activity: (1) a cluster with mild Srxn1-GFP and ICAM1-GFP activation (including azathioprine, mercaptopurine and colchicine); (2) a cluster with strong ICAM1-GFP suppression and CHOP-GFP activation (including nefazodone, clozapine and nitrofurantoin); and, (3) a cluster with mild ICAM1-GFP suppression and activation of Srxn1-GFP and/or CHOP-GFP (including diclofenac, dantrolene, bromfenac and benz bromarone). Overall, Srxn1-GFP responses were often observed in cooperation with the activation of CHOP-GFP and/or ICAM1-GFP reporter activity. This suggests that the Nrf2 activation is a primary cause which also disturb other systems as protein folding or inflammation or that it follows a secondary effect after cellular stress induction. Since we also captured the time dependent adaptive stress activation dynamics, we were able to make a distinction between these two possibilities which both occurred (see Fig. 3 and Suppl. Figures 3 and 4). Interestingly, a very strong decrease in ICAM1-GFP activation coincided with a strong increase in CHOP-GFP activation in a similar concentration response, but no or minor activation of Srxn1-GFP. This is indicative for a specific mode-of-action of these DILI inducing compounds and suggest a relationship between ER-stress induction and suppression of TNFα-mediated NFκB activation and ICAM1 expression. Previously, we demonstrated such a mutual relationship for diclofenac and showed that inhibition of CHOP induction prevented the diclofenac/TNFα-mediated cell death (Fredriksson et al. 2014). For two other drugs in this cluster, nefazodone and clozapine, such a dual modulation of ER-stress and NFκB signaling was demonstrated before (Cosgrove et al. 2009; Laussensergues et al. 2012; Abdel-Wahab and Metwally 2015; Ren et al. 2016). Finally, we observed that a strong enhancement of TNFα-induced ICAM1-GFP activation by DILI inducing compounds was often accompanied with an increase in Srxn1-GFP as well as a decrease in cell number. Since oxidative stress can also lead to NFκB activation, there is a likely synergistic effect for the enhancement of TNFα-mediated NFκB activation. In general, no major increase of p21-GFP activation was observed for most compounds, this is a comforting observation and reflects the genuine exclusion of genotoxic effect of drugs during drug development.

Our systematic screening approach allowed defining of benchmark concentrations for all DILI inducing drugs and the respective reporters. For Srxn1-GFP, CHOP-GFP and ICAM1-GFP we observed a lower ratio of the BMC/C_{max} for severe DILI compared to non-severe DILI inducing drugs, irrespective of the of C_{max} levels. This was especially pronounced in the Srxn1-GFP and CHOP-GFP reporters, indicating that the safe therapeutic window for severe DILI compounds is limited. Therefore, since CHOP is an important adaptation-adversity-switch in ER stress signaling, activation of CHOP may then contribute to liver injury (Yamaguchi and Wang 2004). Since Srxn1-GFP contributes to adaptation, compounds that primarily activate the Nrf2 pathway to a limited extent may still be considered safe (Osburn and Kensler 2009).

The screen was performed in a time-resolved live single cell setting. To date, toxicity screening efforts using high content imaging have mostly focused on single time point fluorescent dyes or anti-bodies (Garside et al. 2014) with several real-time based toxicity screening efforts (Kim et al. 2012). However, the use of dyes and anti-bodies brings additional noise to already very noisy systems as fixation and anti-body binding are likely additional sources of variability; this is not an issue using our reporter models. With the use of our reporter cell lines biological signaling can be visualized with a high time resolution to more accurately pinpoint the primary mode-of-action in relation to cellular stress. Time course signaling data also greatly benefits computational modeling efforts as these require detailed time and dose response dynamics, this is only feasible using live cell imaging data. Furthermore, we were able to extract features based on these time and dose response dynamics. These features were used in support vector machine approach to assess possible differences in cellular adaptive signaling between less- severe and severe DILI. Due to the limited number of no-DILI compounds (n = 16) and the total of 118 compounds tested we had obtained a limited set of observations for building highly accurate predictive models. However, by combining the less-Severe DILI and ambiguous DILI cases together with the no-DILI compounds we were still able to show significant predictivity with an independent subset of our data not used in the SVM tuning process. A ‘predictive toxicogenomics space (PTGS)’ method has recently been defined to determine sensitivity and specificity in classification of known DILI drugs (Kohonen et al. 2017). Although in this study, a different DILI labeling strategy was used, we observed a comparable sensitivity using our limited set of stress response reporters. Interestingly, some of our reporters are reflected by the transcription factors that determine the toxicogenomics-based classifier in the PTGS approach. We anticipate that the discrepancy in the specificity is likely due to the difference in DILI negative labeling approach. We anticipate that the further development of an ever increasing reporter imaging database containing detailed signaling based features linked to chemical exposure, i.e. compound specific biological fingerprints, will ultimately aid in the safety evaluation and early (DILI) prediction of new drugs and chemicals.
We performed the screen using the HepG2 cell line. Although HepG2 has several advantages for in vitro screening (unlimited lifespan, cheap, easy to culture), the major limitation is their lack of metabolic capacity. Interestingly, several compounds that involve biotransformation-dependent toxicity demonstrated activation of an Srxn1-GFP oxidative stress response (e.g. acetaminophen and sulindac). To test whether there is a concordance between the HepG2 BAC-GFP reporters and the transcript levels in primary human hepatocytes we used the TG-GATES dataset to calculate the correlation of the activity of the reporters genes between TG-GATES and the current BAC-GFP HepG2 DILI screen (see Suppl. Figure 5). This indicates a significant correlation of Srxn1 responses at the transcript levels in primary human hepatocyte and protein expression of BAC-GFP reporters in HepG2 cells, also suggestive for a minor role for drug metabolism in the onset of DILI compound-induced stress response activation. Interestingly, for various compounds we did observe induction of stress response pathways that could not be observed in primary human hepatocytes (boxed area, Suppl. Figure 5), thus indicating increased sensitivity of the BAC-GFP reporters for some compounds. Previously, we optimized a HepG2 3D spheroid protocol to enhance liver like properties and to enable chronic exposures (Ramaiah-gari et al. 2014). In future research, we can test whether this would increase prediction of DILI drugs.

In conclusion, we have shown that BAC-GFP reporter cell lines are a sensitive tool to provide detailed mechanistic information regarding the adaptive stress response activation in a broad compound screening setting using high-content live single cell imaging. Such detailed insights into the perturbations of signaling pathways after chemical exposure provides key information for safety assessment and predictive purposes. We anticipate that our BAC-GFP reporter platform will contribute to the early pre-clinical screening for DILI liabilities and possibly also other chemical safety assessment paradigms.

Acknowledgements We would to thank Dr. Weida Tong (NCTR, FDA) for providing DILI compounds and critical discussions. This project was supported by the EU FP7 DETECTIVE Project (Grant no. 266838), the IMI MIP-DILI Project (Grant no. 115336) and the Horizon2020 EU-ToxRisk (Grant no. 681002).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Abdel-Wahab BA, Metwally ME (2015) Clozapine-induced cardio-toxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κB. Cardiovasc Toxicol 15:355–365. https://doi.org/10.1007/s12012-014-9304-9

Andersson TB, Keisu M (2010) Drug-induced liver injury in humans: the case of ximelagatran. In: Uetrecht J (ed) Handbook of experimental pharmacology. Springer, Berlin, pp 407–418

Bae SH, Sung SH, Cho EJ et al (2011) Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology 53:945–953. https://doi.org/10.1002/hep.24104

Bae SH, Sung SH, Lee HE et al (2012) Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury. Antioxid Redox Signal 17:1351–1361. https://doi.org/10.1089/ars.2011.4334

Bandi S, Joseph B, Berishvili E et al (2011) Perturbations in ataxia telangiectasia mutant signaling pathways after drug-induced acute liver failure and their reversal during rescue of animals by cell therapy, Am J Pathol 178:161–174. https://doi.org/10.1016/j.ajpath.2010.11.001

Brenner D, Blaser H, Mak TW (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15:362–374. https://doi.org/10.1038/nri3834

Chen M, Vijay V, Shi Q et al (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16:697–703. https://doi.org/10.1016/j.drudis.2011.05.007

Chen M, Suzuki A, Borlak J et al (2015) Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63:503–514. https://doi.org/10.1016/j.jhep.2015.04.016

Chen M, Suzuki A, Thakkar S et al (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 21:648–653. https://doi.org/10.1016/j.drudis.2016.02.015

Čmielová J, Režáčová M (2011) Protein and its function based on a subcellular localization, J Cell Biochem 112:3502–3506. https://doi.org/10.1002/jcb.23296

Cosgrove BD, King BM, Hasan MA et al (2009) Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 237(3):317–330. https://doi.org/10.1016/j.taap.2009.04.002

Dawson S, Stahl S, Paul N et al (2012) In vivo inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130–138. https://doi.org/10.1124/dmd.111.040758

El-Deiry WS (2016) p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res 76:5189–5191. https://doi.org/10.1158/0008-5472.CAN-16-2055

Espinosa-Diez C, Miguel V, Mennerich D et al (2015) Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol 6:183–197. https://doi.org/10.1016/j.redox.2015.07.008

Findlay VJ, Townsend DM, Morris TE et al (2006) A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 66:6800–6806. https://doi.org/10.1158/0008-5472.CAN-06-0484

Foufelle F, Fromenty B (2016) Role of endoplasmic reticulum stress in drug-induced toxicity. Pharmacol Res Perspect 4:e00211. https://doi.org/10.1010/prp2.211

Fredriksen L, Wink S, Herpers B et al (2014) Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci 140:144–159. https://doi.org/10.1093/toxsci/kfu072
Garside H, Marcove KF, Chesnutt-Speelman J et al (2014) Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol Vitr 28:171–181. https://doi.org/10.1016/j.tiv.2013.10.015

Gaujoux R, Seoighe C (2010) A flexible R package for nonnegative matrix factorization. BMC Bioinform 11:367. https://doi.org/10.1186/1471-2105-11-367

Gustafsson F, Foster AJ, Sarda S et al (2014) A correlation between the in vitro drug toxicity of drugs to cell lines that express human p450s and their propensity to cause liver injury in humans. Toxicol Sci 137:189–211. https://doi.org/10.1093/txsci/kft023

Hoque R, Farooq A, Mahal WZ (2013) Sterile inflammation in the liver and pancreas. J Gastroenterol Hepatol 28:61–67. https://doi.org/10.1111/j.1440-1746.2012.07181.x

Hu Y, Coates ARM (2013) Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. J Antimicrob Chemother 68:374–384. https://doi.org/10.1093/jac/dks384

Jeong W, Bae SH, Toledano MB, Rhee SG (2012) Role of sulfiredoxin as a regulator of peroxiredoxin function and regulation of its expression. Free Radic Biol Med 53:447–456. https://doi.org/10.1016/j.freeradbiomed.2012.05.020

Kametansky L, Jones TR, Fraser A et al (2011) Improved structure, function and compatibility for cellprofiler: modular high-throughput image analysis software. Bioinformatics 27:1179–1180. https://doi.org/10.1093/bioinformatics/btr095

Khetani SR, Kanchagar C, Ukairo O et al (2013) Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 132:107–117. https://doi.org/10.1093/toxsci/kfs326

Kim JA, Han E, Eun CJ et al (2012) Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermurmicolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity. Toxicol Lett 214:175–181. https://doi.org/10.1016/j.toxlet.2012.08.027

Kohonon P, Parkkinen JA, Willighagen EL et al (2017) A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury. Nat Commun 8:1–13. https://doi.org/10.1038/ncomms15932

Laienfeld D, Qiu L, Swiss R et al (2014) Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci 137:234–248. https://doi.org/10.1093/toxsci/kft222

Laressergues E, Bert E, Duriez P et al (2012) Does endoplasmic reticulum stress participate in AIP-induced hepatic metabolic dysregulation? Neuropharmacology 62:784–796. https://doi.org/10.1016/j.neuropharm.2011.08.048

Li Y, Guo Y, Tang J et al (2014) New insights into the roles of CHOP-induced apoptosis in ER stress structure and properties of C/EBP homologous protein roles of CHOP in ER stress-mediated apoptosis. Acta Biochim Biophys Sin 46:629–640. https://doi.org/10.1093/abbs/gmu048.Review

Nidhi K, Indrajeet S, Khushboo M et al (2011) Hydrotropy: a promising tool for solubility enhancement: a review. Int J Drug Dev Res 3:26–33. https://doi.org/10.1002/jps

O’Brien PJ, Irwin W, Diaz D et al (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580–604. https://doi.org/10.1007/s00204-006-0091-3

Ogutu BR, Newton CRJC., Muchohi SN et al (2002) Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol 54:635–642. https://doi.org/10.1046/j.1365-2125.2002.01689.x

Osburn WO, Kensler TW (2008) Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 659(1–2):31–39. https://doi.org/10.1016/j.mrrev.2007.11.006

Patel CG, Li L, Girgis S et al (2011) Two-way pharmacokinetic interaction studies between saxagliptin and ciprotrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol Adv Appl 3:13–25. https://doi.org/10.2147/CPAA.S15227

Rahman A, Fazal F (2009) Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration. Antioxid Redox Signal 11:823–839. https://doi.org/10.1089/ars.2008.2204

Ramaiahgari SC, Den Braver MW, Herpers B et al (2014) A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol 88:1083–1095. https://doi.org/10.1007/s00204-014-1215-9

Raschi E, de Ponti F (2015) Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. World J Hepatol 7:1761–1771. https://doi.org/10.4245/wjh.v7.i13.1761

Raschi E, de Ponti F (2017) Drug-induced liver injury: towards early prediction and risk stratification. World J Hepatol 9:30–37. https://doi.org/10.4245/wjh.v9.i10.30

Ravic M, Warrington S, Boyce M et al (2004) Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. Br J Clin Pharmacol 58(Suppl 1):34–40. https://doi.org/10.1111/j.1365-2125.2004.01800.x

Regenthal R, Krueger M, Koeppel C, Preis R (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 15:529–544. https://doi.org/10.1023/A:1009935116877

Ren Z, Chen S, Zhang J et al (2016) Endoplasmic reticulum stress induction and ERK1/2 activation contribute to nefazodone-induced toxicity in hepatic cells. Toxicol Sci 154:368–380. https://doi.org/10.1093/toxsci/kfw173

Ritz C, Baty F, Streibig JC, Gerhard D (2015) Dose-response analysis using R. PLoS One 10:1–13. https://doi.org/10.1371/journal.pone.0146021

Schmidt D, Einnicke I, Haenel F (1986) The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol 43:263–265. https://doi.org/10.1001/archneur.1986.0052003053013

Shaw PJ, Beggs KM, Sparkenbaugh EM et al (2009) Trofavoxadin enhances TNF-induced inflammatory stress and cell death signalling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci 111:288–301. https://doi.org/10.1093/toxsci/kfp163

Tian B, Nowak DE, Brasier AR (2005) A TNF-induced gene expression program under oscillatory NF-κB control. BMC Genom 6:1–18. https://doi.org/10.1186/1471-2164-6-137

Wickham H (2009) ggplot2 elegant graphics for data analysis. Media 35:211. https://doi.org/10.1007/978-0-387-98141-3

Wink S, Hiemstra S, Huppelschoten S et al (2014) Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem Res Toxicol 27:338–355. https://doi.org/10.1021/tx4004038

Wink S, Hiemstra S, Herpers B, van de Water B (2017) High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol 91:1367–1383. https://doi.org/10.1007/s00204-016-1781-0

Wu KC, Liu JJ, Klaassen CD (2012) Nrf2 activation prevents cadmium-induced acute liver injury. Toxicol Appl Pharmacol 263:14–20. https://doi.org/10.1016/j.taap.2012.05.017
Xu JJ, Henstock PV, Dunn MC et al (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97–105. https://doi.org/10.1093/toxsci/kfn109

Yafune A, Taniai E, Morita R et al (2013) Expression patterns of cell cycle proteins in the livers of rats treated with hepatocarcinogens for 28 days. Arch Toxicol 87:1141–1153. https://doi.org/10.1007/s00204-013-1011-y

Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279:45495–45502. https://doi.org/10.1074/jbc.M406933200

Yan K, Verbeek FJ (2012) Segmentation for high-throughput image analysis: watershed masked clustering. In: Margaria T, Steffen B (eds) Lecture notes in computer science (including subseries lecture notes in artificial intelligence and lecture notes in bioinformatics). Springer, Berlin, pp 25–41